Carcinogenesis Program Direction Changes Near for Extramural research; Workshop Topics Listed
In Brief: Best Guess On NCI Director: Brown First Choice, Benacerraf Second; FDa On Saccharin
NCI Advisory Groups To Be Cut By One-Third
Graalman Objects To Criticism On Contract Competition
Abstracts Of Papers From Conference On Adjuvant Therapy
Trending Stories
- DOD cancer research programs face 57% funding cut in year-long continuing resolution
Pancreatic, lung, kidney cancer research programs eliminated - What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns” - Kennedy announces massive cuts, centralization at HHS—NCI and FDA hit
Also this week: Columbia yields, Makary and Bhattacharya confirmed, tariffs on pharmaceuticals, and more changes impacting oncology - In The Headlines: HHS shakeup threatens a legacy of medical breakthroughs
- Karen Knudsen tells us why she took the CEO job at the Parker Institute for Cancer Immunotherapy
- Brian Druker, developer of Gleevec, eyes a new feat: Setting the Boston Marathon fundraising record
Current record: $507,000. Proceeds to go to LLS as NIH funding is slashed